China's NMPA has granted approval for Keymed Biosciences’ supplemental NDA of Stapokibart to treat seasonal allergic rhinitis ...

Allergic rhinitis is the inflammation of nasal passageways that occurs when your immune system overreacts to allergens such as pollen, pet dander, or dust mites that are in the air. When it's ...

KEY POINTS Chronic rhinosinusitis refers to symptomatic inflammation of the nose and paranasal sinuses that has been present ...

For some people, the classic symptoms of a sinus infection, including nasal congestion and discharge, are also accompanied by ...

The presence and type of asthma is influenced by sensitization, and the duration and severity of allergic rhinitis. Nasal symptoms, airflow and markers of inflammation directly correlate with ...

KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of ...

Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...

This can make nasal and sinus symptoms worse. “In patients who are having a longstanding problem, like allergic rhinitis or asthma in the nose, we usually want to check in about six to eight weeks to ...

placebo-controlled phase III study to confirm the efficacy and safety of Stapokibart injection in treatment of adult patients with seasonal allergic rhinitis who are poorly controlled with nasal ...

Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...